Standard

Intravenouse immunoglobuline in dysautonomia. / Gavrilova, N.; Kamaeva, E.; Ignatova, M.; Ryabkova, V.; Lukashenko, M.; Soprun, L.; Churilov, L.P.; Shoenfeld, Y.

In: Clinical Immunology, Vol. 240, 109039, 07.2022.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

BibTeX

@article{9b025bb3f91e4ea09c5378f0d6420d1a,
title = "Intravenouse immunoglobuline in dysautonomia",
abstract = "Nowadays intravenous immunoglobulin (IVIg) treatment is considered to play a promising role in the autoimmune disease therapy. Despite its significant beneficial effects, the precise mechanism of action needs further studies, as well as recommended dosage in the treatment of autoimmune dysautonomia. In some diseases, like Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating neuropathy (CIDP), IVIg has a strong evidence that allows to recommend and prescribe the medication, while in other diseases only single case studies are available that requires further research. The review summarizes the currently available information on the effectiveness of IVIg in primary autoimmune neuropathies and neurological complications of systemic diseases, as well as side effects, features of clinical use with an emphasis on doses and treatment protocols in dysautonomia. Being safe and effective therapy, immunologic treatment is one of the most promising tools to achieve clinical remission of dysautonomia and good quality of life in autoimmune patients.",
keywords = "Autoimmune autonomic gangliopathy (AAG), Neuropathy, Chronic inflammatory demyelinating neuropathy (CIDP), Guillain-Barre syndrome (GBS), Small fiber neuropathy (SFN), Intravenous immunoglobulins",
author = "N. Gavrilova and E. Kamaeva and M. Ignatova and V. Ryabkova and M. Lukashenko and L. Soprun and L.P. Churilov and Y. Shoenfeld",
note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = jul,
doi = "10.1016/j.clim.2022.109039",
language = "English",
volume = "240",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Intravenouse immunoglobuline in dysautonomia

AU - Gavrilova, N.

AU - Kamaeva, E.

AU - Ignatova, M.

AU - Ryabkova, V.

AU - Lukashenko, M.

AU - Soprun, L.

AU - Churilov, L.P.

AU - Shoenfeld, Y.

N1 - Publisher Copyright: © 2022 Elsevier Inc.

PY - 2022/7

Y1 - 2022/7

N2 - Nowadays intravenous immunoglobulin (IVIg) treatment is considered to play a promising role in the autoimmune disease therapy. Despite its significant beneficial effects, the precise mechanism of action needs further studies, as well as recommended dosage in the treatment of autoimmune dysautonomia. In some diseases, like Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating neuropathy (CIDP), IVIg has a strong evidence that allows to recommend and prescribe the medication, while in other diseases only single case studies are available that requires further research. The review summarizes the currently available information on the effectiveness of IVIg in primary autoimmune neuropathies and neurological complications of systemic diseases, as well as side effects, features of clinical use with an emphasis on doses and treatment protocols in dysautonomia. Being safe and effective therapy, immunologic treatment is one of the most promising tools to achieve clinical remission of dysautonomia and good quality of life in autoimmune patients.

AB - Nowadays intravenous immunoglobulin (IVIg) treatment is considered to play a promising role in the autoimmune disease therapy. Despite its significant beneficial effects, the precise mechanism of action needs further studies, as well as recommended dosage in the treatment of autoimmune dysautonomia. In some diseases, like Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating neuropathy (CIDP), IVIg has a strong evidence that allows to recommend and prescribe the medication, while in other diseases only single case studies are available that requires further research. The review summarizes the currently available information on the effectiveness of IVIg in primary autoimmune neuropathies and neurological complications of systemic diseases, as well as side effects, features of clinical use with an emphasis on doses and treatment protocols in dysautonomia. Being safe and effective therapy, immunologic treatment is one of the most promising tools to achieve clinical remission of dysautonomia and good quality of life in autoimmune patients.

KW - Autoimmune autonomic gangliopathy (AAG)

KW - Neuropathy

KW - Chronic inflammatory demyelinating neuropathy (CIDP)

KW - Guillain-Barre syndrome (GBS)

KW - Small fiber neuropathy (SFN)

KW - Intravenous immunoglobulins

UR - https://www.mendeley.com/catalogue/92b482f3-d50d-3946-8d39-49390e1875ac/

UR - http://www.scopus.com/inward/record.url?scp=85131558429&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2022.109039

DO - 10.1016/j.clim.2022.109039

M3 - Review article

C2 - 35569781

VL - 240

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

M1 - 109039

ER -

ID: 95104994